Investor Relations

Evelo Biosciences is a clinical-stage company pioneering the development of monoclonal microbials, a new class of therapies designed to act on the gut-body network. Monoclonal microbial product candidates are orally-delivered pharmaceutical compositions of specific strains of naturally-occurring microbes and are intended to modulate systemic immune response by acting on the gut-body network through multiple naturally-evolved biological pathways. Evelo believes monoclonal microbials have the potential to be broadly applicable across many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.